University of Vermont

UVM ScholarWorks
UVM Honors College Senior Theses

Undergraduate Theses

2022

Characterizing the Effects of Vaccine Adjuvants on Skeletal
Muscle Myotubes and Macrophages
Aliceson L. Drollette
University of Vermont

Joseph J. Bivona
University of Vermont

Matthew E. Poynter
University of Vermont

Follow this and additional works at: https://scholarworks.uvm.edu/hcoltheses

Recommended Citation
Drollette, Aliceson L.; Bivona, Joseph J.; and Poynter, Matthew E., "Characterizing the Effects of Vaccine
Adjuvants on Skeletal Muscle Myotubes and Macrophages" (2022). UVM Honors College Senior Theses.
462.
https://scholarworks.uvm.edu/hcoltheses/462

This Honors College Thesis is brought to you for free and open access by the Undergraduate Theses at UVM
ScholarWorks. It has been accepted for inclusion in UVM Honors College Senior Theses by an authorized
administrator of UVM ScholarWorks. For more information, please contact scholarworks@uvm.edu.

Characterizing the Effects of Vaccine Adjuvants on Skeletal Muscle
Myotubes and Macrophages

A Thesis Presented by Aliceson L. Drollette1
To the Faculty of the College of Arts and Sciences
of the University of Vermont

In Partial Fulfillment of the Requirements
of the University of Vermont Honors College
and Bachelor of Arts in Biology

May 2022

Co-Authors
Joseph J. Bivona III, Ph.D.2
Matthew E. Poynter, Ph.D.2

Committee Members
Jim O. Vigoreaux Ph.D.1, Thesis Advisor
Matthew E. Poynter, Ph.D.2, Chairperson
Carolyn Morris, Ph.D.3

Affiliations
Department of Biology, University of Vermont, 109 Carrigan Dr., Burlington, VT 05405
2
Department of Medicine, University of Vermont, 89 Beaumont Ave., Burlington, VT 05405
3
Department of Medicine, University of Vermont, 149 Beaumont Ave., Burlington, VT 05405
1

1

Abstract
Vaccines train the immune system to recognize and defend against pathogens. Currently,
six types of vaccines are in use and include live-attenuated, inactivated, viral vector, protein
subunit, toxoid, and messenger RNA (mRNA), the latter of which was recently approved for
humans during the COVID-19 pandemic. To increase the longevity and magnitude of immune
responses, some vaccines are combined with adjuvants. Mouse models have shown that
adjuvants in combination with antigens can elicit a pro-inflammatory immune system response
that is required for proper development of protective immunity. There has been recent
appreciation for the immunomodulatory functions of skeletal muscle, yet their contribution to the
immunology of vaccination remains incompletely understood. Considering most vaccines are
administered intramuscularly, we utilized C2C12 mouse myotubes and J774 macrophages to
explore the cytokine response that skeletal muscle cells and macrophages evoke in response to
several types of vaccine adjuvants in absence of the antigen. C2C12 myotubes and J774
macrophages were treated with 7 commonly used adjuvants or appropriate controls and collected
at 6 hours and 24 hours. Cytokine secretion, cytotoxicity, and effects on myotube diameter were
analyzed. Most adjuvants, except for the positive controls (LPS and PAM3CSK4), CpG 1826,
and Quil-A, did not induce a pro-inflammatory response in C2C12 myotubes or J774
macrophages. Interestingly, LPS, PAM3CSK4, MF59, Quil-A, AS03, and CFA, led to increases
in C2C12 myotube diameter indicating an activation of hypertrophy. The lack of proinflammatory effects indicates that most adjuvants need antigens or additional cell-cell
interactions at the injection site to produce a pro-inflammatory cytokine response.
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Introduction
This study focuses on analyzing both qualitatively and quantitatively the impact that
commonly used vaccine adjuvants, including aluminum salts, MF59, AS03, CpG 1018, and
Quil-A, have on skeletal myocytes and J774 macrophages. We ask, how does the use of
adjuvants in vaccines influence the immune response and its’ function? Analysis of the C2C12
mouse myoblast model system and J774 macrophage model system will allow for the
comparison of these different adjuvants and their subsequent effects on the body.
The Importance of Muscle in Vaccination
In the late 1990s, it was discovered that the activation of cell surface and intracellular
receptors, such as toll-like receptors (TLRs), can stimulate dendritic cells (DCs), which play a
critical role in initiating subsequent antigen-specific T and B cell responses1. Skeletal muscle
cells also express multiple TLRs, which supports the possibility of a response to environmental
factors to induce the production of inflammatory cytokines and possibly to promote adaptive
responses necessary for immunological memory.
Most vaccines used in humans are administered intramuscularly, specifically within the
scapular region at the deltoid muscle. Proper injection technique facilitates protective immunity.
If a vaccine is injected into a layer of subcutaneous fat, it may result in a slow mobilization and
processing of the antigen. Additionally, subcutaneous vaccination more frequently results in
unwanted local reactions, such as erythema, rashes, and irritation. To fulfill requirements for
clinical use, vaccine delivery must have minimal local reactogenicity and limited pain, both of
which are more reliably avoided using intramuscular injection2. One proposed mechanism by
which intramuscular administration avoids the harmful effects of subcutaneous injections is due
to the abundant blood supply within skeletal muscle. Therefore, vaccines administered into the
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muscle are generally absorbed into the vasculature quickly. However, local immunogenic
responses, such as heat, pain, redness, and swelling (calor, dolor, rubor, and tumor) as first
described by the Roman scholar Celsus in the first century CE, can occur but to a much less
extent than subcutaneous injections3. Although considered by vaccine recipients to be an
undesired side effect, these events promote immune cell recruitment and activation, which may
modulate the efficiency of the subsequent vaccine-elicited immune response.
Dendritic cells are one of the most important cell types for inducing protective immunity.
They function by bringing the antigen to the draining lymph node, which in the case of
intramuscular injections into the deltoid, is the axillary (armpit) lymph node. Studies have
concluded that lymph nodes, specifically in the axillary and inguinal (groin) region have the
highest concentrations of DCs. Muscle and the subcutaneous layer both have a low density of
dendritic cells (DCs), which is why commercial vaccines frequently use adjuvants to increase
DC activation and recruitment4. The contributions of myocytes to vaccine adjuvant elicited
immune responses are important since these cells are likely contributors to the generation of a
more protective adaptive immune response. Controlling the activities of these muscle cells to
potentially mitigate the unwanted side-effects of poor efficacy adaptive immune responses is a
necessary research objective.
Importance of Adjuvants in Vaccines
Adjuvants are used in common vaccines such as Hep B and HPV to help the body
produce an immune response. They have been safely used in vaccines since 1932, and through
advancing technology newer adjuvants have been developed to target specific components of the
body’s immune response. Our immune response is how the body recognizes and defends itself
against bacteria, viruses, and other harmful exogenous and endogenous substances. Adjuvants
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can improve the immune response in numerous ways, including enhancing the speed and
duration of the immune response and stimulating cellular immunity.

Figure (1). Timeline from 1900 to 2020 of commonly used vaccine adjuvants for varying diseases and
purposes (Adapted from “Timeline of Adjuvant Used in Human Vaccines”, by BioRender.com (2022)).

Since 1932, there are five adjuvants, aluminum-containing salts (commonly referred to as
Alum), MF59, AS01, AS04, and CpG 1018, that have been used clinically in the United States5.
While the number of approved vaccines continues to increase, the relatively low number of
adjuvants attests to their safety and efficacy (Figure 1). Despite their widespread use, the
molecular mechanisms of how these adjuvants function remain incompletely understood.
Whereas some adjuvants function through several complementary physical, cellular, and
biochemical means, the major focus of adjuvant discovery in the past decade has been targeted to
their activation of TLR signaling pathways, although other pattern recognition receptors can also
be targeted1.

5

Vaccine Adjuvants
TLR Agonists
Lipopolysaccharides (LPS) are cellular wall components of Gram-negative bacteria that
function as TLR4 agonists. LPS molecules composed of a hydrophobic lipid, a hydrophilic core
polysaccharide, and a hydrophilic O-antigenic polysaccharide side chain, composed of repeated
units of oligosaccharides. LPS is not currently used in any distributed vaccines, although several
of its’ characteristics make it a viable choice for live attenuated vaccines in the future. These
properties include that it is important to bacterial survival, has a marked pathogen associated
molecule pattern (PAMP), and triggers specific antibody responses conferring protective
immunity6. LPS is referred to as a natural adjuvant that increases the number of cell divisions
and the rate of cell survival during and after T cell activation and clonal expansion. Low toxicity
LPS has previously been found to induce responses indicating that these molecules are able to
act as immunological adjuvants for specific humoral immunity and the enhancement of IgG titers
but would be unable to serve as an adjuvant for cellular or cytotoxic T lymphocyte responses7.
For the studies presented in this thesis, LPS is used as a positive control.
PAM3CysSerLys4 (PAM3CSK4) is a synthetic triacylated lipopeptide and a TLR2/TLR1
ligand. It has proven to be a potent adjuvant for various vaccines, including a sublingual allergy
vaccine and leishmaniasis vaccine8. Results from a preclinical study, showed that PAM3CSK4
increases antibody responses to flu antigens unlike other TLR ligands. PAM3CSK4 was also
found to enhance B cell activation through increased levels of cytokine secretion and
proliferation9. For the studies presented in this thesis, PAM3CSK4 is used as a positive control.
CpG oligonucleotides (ODNs) contain a full phosphonothioate backbone with one or
more CpG dinucleotides in a particular sequence context, named CpG motifs. CpG ODNs
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specifically activate TLR9, leading to strong immunostimulatory effects. Currently, the only
CpG ODNs in an available vaccine is CpG 1018 in Heplisav-B. The TLR9 agonist, CpG 1826, is
a class B CPG ODN specific for mouse TLR9, which stimulates strong B cell activation and
generates a Th1-dominant immune response10. The expression of TLR9 is stronger and more
present in mice compared to humans, although this TLR9 expression is mostly limited to
plasmacytoid dendritic cells and B cells.
Aluminum-based Adjuvants
Alum is the most used adjuvant, and it induces antibody responses and CD4 T helper cell
responses in humans1. The composition of alum includes one or more of the following:
amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum
phosphate, and potassium aluminum sulfate. Alum is currently used in the Anthrax, Hep A, Hep
B, HPV, and Tdap vaccines. An alum-elicited immune response study in mice involved
removing the critical adaptor proteins involved in TLR signaling, namely MyD88 and TRIF,
with results showing that the immune responses stimulated by immunization with alum and
antigen were unaffected. This result suggested that the effects of alum occur through a
mechanism independent of TLR signaling. Alum can enhance adaptive immunity by causing
tissue damage that activates inflammatory dendritic cells, as well as by recruiting neutrophils to
release neutrophil extracellular traps (NETs)10. Aluminum salts have the capability of
transforming soluble antigens into colloids, which are more effectively internalized and can
enhance MHCII expression (necessary for CD4 T cell activation to initiate immune responses)
on antigen-presenting cells11, 12.
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Oil-in-Water and Water-in- Oil Adjuvants
MF59 (Addavax) is an oil-in-water emulsion adjuvant composed of squalene that
activates myeloid cells, such as macrophages and dendritic cells, to produce chemokines that
further recruit neutrophils, eosinophils, and monocytes to the injection site10. This adjuvant is
currently used in the FLUAD vaccine, which is an inactivated influenza vaccine. Studies
conducted in mice have demonstrated that MF59 induces a wider range of cytokines and
chemokines compared to alum. MF59 requires the MyD88 adapter protein to transduce signals
leading to the release of ATP from muscle cells13, 14.
The AS0 adjuvant systems were developed to obtain maximal adjuvant effect by creating
a rational combination of classical adjuvant molecules and immunostimulatory molecules.
Within the AS0 adjuvant family, the AS04 adjuvant, which is composed of monophosphoryl
lipid A (MPL) and an aluminum salt, is the adjuvant in the Cervarix vaccine. The AS01B
adjuvant composed of MPL and QS-21 (a detoxified saponin derivative) is found in the Shingrix
vaccine. AS03 (Addavax) is composed of α-tocopherol, squalene and polysorbate 80 in an oil-inwater emulsion and is found in the avian influenza vaccine. Specifically, AS03 has been shown
to trigger transient NF-B- dependent innate immune responses, which results in the production
of cytokines and chemokines15 (Figure 2).
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Figure (2). Graphic depicting the subsequent immune response, with the differing cell types, after the
injection of a vaccine of AddaS03 and an antigen into the deltoid muscle of a human participant.

The Quil-A adjuvant is a saponin adjuvant, which typically induces a strong cytotoxic
CD8+ lymphocyte response and potentiates the response to mucosal antigens. The Quil-A
adjuvant is used in a wide variety of veterinary vaccines but is not currently approved for use in
human vaccines. This adjuvant can induce a strong response to both T-dependent and Tindependent antigens. The Quil-A adjuvant has been proven to activate the antibody-mediate
immune responses to a broad range of viral, bacterial, and parasitic antigens.
Complete Freund’s Adjuvant (CFA) contains heat killed Mycobacterium tuberculosis in
paraffin oil and mannide monooleate. Water-in-oil emulsions of antigens can be created with
CFA. This adjuvant induces a Th1-dominated response when injected with an antigen. CFA is
currently not used in human vaccines, because it has been linked with the potential to interfere
with TB test results and cause excessive inflammation. Prior studies showed that CFA injection
with an antigen led to increased infiltration of muscle with granulocytes, macrophages, and
dendritic cells16.
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mRNA Delivery Agent
Mirus TransIT-mRNA is considered a high efficiency, low toxicity transfection reagent
for large RNA molecules. This type of adjuvant is considered a delivery agent responsible for
transferring RNA species into mammalian cells. TransIT-mRNA is not currently used in any
licensed mRNA vaccines. The only mRNA vaccines currently used in humans are the COVID19 vaccines that contains the mRNA that directs cells to produce copies of the SARS-CoV-2
spike protein. mRNA research in the scientific community has increased dramatically due to the
importance of the COVID-19 vaccine during the pandemic. Unprotected mRNA delivered by
itself is unsuitable for broad applications, making strategies for RNA delivery to the cytosol
necessary17. Studies have shown that the TransIT reagent yields high transfection levels of
human pluripotent stem cell derived cardiomyocytes in vitro compared to other reagents, such as
jet MESSENGER or MessengerMAX modRNA18.
Prior Literature
Various live organism-based vaccines exhibit high efficacy; however, this is often
associated with adverse local and/or systemic reactions. Comparatively, sub-unit proteins offer a
much lower risk alternative, although their efficacy is typically low. The use of adjuvant systems
to enhance the effectiveness of sub-unit vaccines has proven effective by preventing the
degradation of the antigen as well as enhancing the targeting of these antigen by antigen
presenting cells(APCs), such as dendritic cells19. To induce a cascade of events leading to a large
pro-inflammatory response, adjuvants may need to be used where multiple cell types are present
and their activation can be stimulated with an antigen. For example, adjuvants are believed to
increase the innate immune response to antigen by interacting with pattern recognition receptors
(PRRs), such as the TLRs and other types of innate immune receptors.
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In 1989, Charles A. Janeway, a noted immunologist credited with helping to create the
modern field of innate immunity, said that adjuvants are “the immunologists’ dirty little secret”
and speculated on the existence of PRRs, which he proved existed a few years later20. In the
subsequent decades, their function, and mechanisms to elicit immune responses are becoming
understood. Mechanisms of PRR-elicited effects include sustaining the release of an antigen, the
upregulation of cytokines and chemokines, cellular recruitment, increased antigen uptake,
activation and maturation of APCs, and activation of the NLRP3 inflammasome21.
Cytokines are small proteins that are crucial in controlling the growth and activity of cell
types, including immune system cells, in addition to impacting the body’s immune and
inflammation responses. Cytokines can be broken down into two classes, pro-inflammatory and
anti-inflammatory. Interleukin-6 (IL-6) is known as the chief stimulator of the production of
most acute phase proteins, which are the proteins responsible for the initial response of the
organism against infection or tissue damage22. Monocyte chemotactic protein-1 (MCP-1) is a
chemokine that regulates the migration and infiltration of monocytes and macrophages in the
body. Interleukin-15 (IL-15) is a pleiotropic cytokine produced by myocytes (therefore, often
termed a ‘myokine’) that functions in the development of inflammatory and protective immune
responses23.
The Impact of the COVID-19 Pandemic
Adjuvant research is extensively needed before the implementation of certain adjuvants
into developing vaccine formulations. The COVID-19 pandemic is a prevalent global issue of the
effects of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2). As of April 2022, this pandemic has caused more than 550 million cases and
6.18 million deaths24. Preventive measures, including social distancing, masking, and improved
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ventilation, and air filtration, were recommended and in many countries, enforced while vaccines
were being developed25. In December 2020, the first COVID-19 mRNA vaccines were
administered separately by Pfizer-BioNTech and Moderna to provide cells the instructions
necessary to produce the spike (S) protein found on the surface of SARS-CoV-2. Post
vaccination, the cells at the local injection site begin to make the spike (S) protein pieces and
display them on their cellular surfaces. This leads to the production of antibodies and the
induction of immunological memory if the vaccinated individual was to become infected with
the COVID-19 virus. These mRNA vaccines are used to help prevent severe illness from the
COVID-19 infection, but have varying efficacy to protect individuals from getting COVID-19.
During the development of the Pfizer-BioNTech and Moderna vaccine, the avoidance of
aluminum-based adjuvants (ABAs) was distinctly made. Researchers were concerned that since
cytokine storms, which are an extremely strong and potentially dangerous immune response,
were observed in severe COVID-19 cases, that similar responses could occur with the addition of
these ABAs. Additionally, intense cytokine production can affect RNA translation11. As of 2021,
AS03 and CpG 1018 were being developed as adjuvants for use in subunit SARS-CoV-2
vaccines. A recent study testing the effectiveness of specific adjuvants in application with the
SARS-CoV-2 vaccines found that CpG 1018 stimulated a Th1 biased response, Alum and oil-inwater adjuvant induced a Th2 biased response, and AS03 stimulated a mixed Th1/Th2 response
26

. Currently, the US manufactured Pfizer-BioNTech and Moderna COVID-19 vaccine do not

contain any adjuvants.
In India, the COVAXIN COVID-19 vaccine was developed and manufactured. This
vaccine is an inactivated SARS-CoV-2 that uses adjuvant Alhydroxiquim-II (AHQ-II) to boost
immune response and promote longer-lasting immunity. This novel adjuvant was developed in
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the United States and is comprised of a small molecule imidazoquinolinone TLR 7/8 agonist
(IMDG) attached to Alhydrogel (a form of alum). AHQ-II induces Th1- biased immunity and
was found to increase neutralizing antibodies titers by approximately 1000-fold in an inactivated
SARS-CoV-2 vaccine27.
Gaps in the understanding of adjuvants have led us to the following research questions:
How do vaccine adjuvants affect skeletal muscle cell and macrophage inflammatory response?
What cytokine and chemokine products are being created by these cell types? By using in vitro
methods with the C2C12 mouse skeletal muscle cell line and the J774 murine macrophage cell
line, it is possible to focus the study on isolated cell groups as well as the coculture of the
C2C12s and J774s. There are other cell types present in skeletal muscle tissues including
connective tissue cells, dendritic cells, satellite cells and lymphocytes. By removing those
additional cell types, we can investigate the contribution of muscle cells and macrophages alone
through adjuvant stimulation. We hypothesize that vaccine adjuvants will promote the immune
response in muscle by eliciting a pro-inflammatory cytokine response.
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Methods
C2C12 Skeletal Muscle Cell Passage
C2C12 mouse myoblasts were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). C212 aliquots (1 million cells in 10% dimethyl sulfoxide
(DMSO) and 90% fetal bovine serum (FBS)) were removed from liquid nitrogen and thawed
under hot running water. Immediately after thawing, the cells were transferred to a 15 mL
conical tube containing 10 mL of growth media consisting of low glucose (1g/L) Dulbecco’s
Modified Eagle Media (DMEM) supplemented with 10% FBS and 1% penicillin and
streptomycin (GIBCO, Thermo Fisher Scientific, Waltham, MA, USA).
The cells were spun at 250 RCF at 22°C for 5 minutes. The supernatant was aspirated,
and the pellet was resuspended in 1 mL of growth media. New passages were started with
300,000 cells in 12 mL of growth media in T75 flasks (Thermo Fisher Scientific, Waltham, MA,
USA) and grown in a cell culture incubator (5% CO2 at 37°C).
At approximately 70% confluency the cells were passaged into new flasks. To do so, the
growth media was aspirated, and the cells were washed with 3-5 mL of phosphate-buffered
saline (PBS) (GIBCO). PBS was aspirated, and 3 mL of 1.33 concentration of Trypsin (GIBCO)
in PBS was added and the cells were incubated for 3 minutes. Once the cells were lifted from the
flask, the contents were transferred to a 15 mL conical tube containing 10 mL of growth media.
The cells were spun at 250 RCF at 22°C for 5 minutes. The supernatant was aspirated, and the
pellet was resuspended in 1 mL of growth media. New passages were started with 300,000 cells
in 12 mL of growth media in T75 flasks and grown in a cell culture incubator (5% CO2 at 37°C).
This protocol continued until the cells are used in experiments or they reached passage 9.
C2C12 Cell Plating
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Before plating the cells, 24 well plates (CELLTREAT Scientific Products, Pepperell,
MA, USA) were coated with gelatin cross linked with microbial transglutaminase (MTG).
Briefly, a 10% w/v gelatin solution was incubated at 65°C and mixed at a ratio of 9 parts gelatin
to 1 part 40% MTG. Then, 60 μL of the solution was immediately added to the 24 well plate and
allowed to cure overnight. The following day, the plates were rehydrated with PBS. Cells were
collected from the T75 flasks following the passage protocol and transferred to a 50 mL conical
tube. Cells were suspended at 70,000 cells per mL and 0.5 mL were added to each well. Cells
were grown to 100% confluency over 24 hours at which point growth media was removed and
differentiation media containing high glucose (4.5 g/L) DMEM, 2% FBS, and 1%
penicillin/streptomycin (GIBCO) was added. The media within the wells was changed daily for a
period of 7 days to achieve fully differentiated C2C12 cells.
J774 Cell Passaging
J774 mouse macrophages were purchased from ATCC. J774 aliquots (J774 cells in
DMEM modified to contain 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate,
and 1500 mg/L sodium bicarbonate) were removed from liquid nitrogen at and thawed under hot
running water. Once completely thawed, the contents were transferred to a 15 mL conical tube
and 9 mL of growth media (DMEM modified to contain 4 mM L-glutamine, 4500 mg/L glucose,
1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate with 10% FBS) (ATTC) was added.
The conical tube was spun at 250 RCF at 22°C for 5 minutes. The supernatant was
aspirated, and the remaining cells were resuspended in 1 mL of growth media. New passages
were started with 1,000,000 cells in 12 mL of media in T75 flasks and grown in a cell culture
incubator (5% CO2 at 37°C).
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At 70% confluency the cells were passaged into new flasks. The cells were scraped then
transferred into a 15 mL conical tube and spun between 250 RCF at 22°C for 5 minutes. The
same process was completed on the cells during passage until the cells were plated or they
reached passage 40.
J774 Cell Plating
24 well plates (CELLTREAT) were used without a gelatin-MTG coating to plate the
J774 cells. Cells were collected from the T75 flasks following the passage protocol and
transferred to a 50 mL conical tube. Cells were suspended at 1 *106 cells/ mL and 0.5 mL was
added to each well on the plate. Cells were grown to 100% confluency over 24 hours, and then
the media was aspirated, and the adjuvant treatment initiated.
Coculture of C2C12 and J774 Cell Plating
Like C2C12 plating, 24 well plates (CELLTREAT) were coated with a gelatin-microbial
transglutaminase substrate. Cells were collected from the T75 flasks following the passage
protocol and transferred to a 50 mL conical tube. Cells were suspended at 70,000 cells per mL
and 0.5 mL were added to each well on the plate. C2C12 cells were grown and differentiated as
stated previously. On day 6, J774 cells were added to the wells containing the C2C12 cells at
2,600 cells per cm2 of media. On day 7, the adjuvant treatment was initiated.
Adjuvant Treatment
The adjuvants (concentrations and sources are listed in Table 1) were diluted in
differentiation media (2% FBS, 1% pen/strep) for the 6 hour and 24-hour treatment with the
C2C12 cells, in addition to the 6-hour treatment with the coculture of C2C12 and J774 cells. In
J774 monoculture experiments, the adjuvants were diluted to the appropriate concentrations
using J774 growth media.
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Table 1: Treatment Concentrations
Adjuvant Treatment

Concentration

Company

Concentration
Selection

LPS (positive control)
PAM3CSK4 (positive
control)
AddaVax
AddaS03
CpG 1826
Non CpG 2138
AlOH
CFA
Quil-A
Mirus TransIT

1 μg/ mL
1 μg/ mL

Sigma
Sigma

28

1:100 (v:v)
1:30 (v:v)
10 μg/ mL
10 μg/ mL
40 μg/ mL
1:30 (v:v)
1 μg/ mL
1 μl mRNA boost reagent,
1 μl TransIT-mRNA
reagent

Invivogen
Invivogen
Coley Pharmaceuticals
Coley Pharmaceuticals
Thermo Scientific
Invivogen
Sigma
Mirus

29

8

30
31
31
32
30
33

Manufacturer’s
Indications

Image Collection and Analysis
Images of individual wells were acquired using a microscope digital camera (AmScope)
in duplicates for one well of each of the 24-hour C2C12 adjuvant treatment at 10x under a light
microscope. Using the program ImageJ, 5 measurements for each myotube were determined for
30 myotubes. The average diameter for the myotubes in each photograph was subsequently
calculated.
Collection of Lysates and Supernatants
For each well, the supernatant was collected and placed into 1.5 mL microcentrifuge
tubes (USA Scientific, Ocala, FL, USA). Following supernatant removal, 200 μL of Trizol was
added to each well and incubated for 3 minutes at 20°C. The lysate in each well was collected
and placed into separate 1.5 mL microcentrifuge tubes. Lysates and the supernatants were stored
in a -80°C freezer.
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Enzyme-Linked Immunosorbent Assay (ELISA)
All ELISA assays were conducted using commercially available kits, that were prepared
according to the manufacturer’s protocols (Duoset ELISAs by R&D Systems, Minneapolis, MN,
USA) to measure serum cytokines IL-6, IL-15, and MCP-1. High binding 96-well plates were
coated overnight at 20°C with the appropriate capture antibody diluted in coating buffer (1X
PBS). The following day, the plates were washed three times in wash buffer (0.05% Tween20 in
PBS). The protein binding sites in the wells on the plates were then blocked in 1% BSA in PBS
for at least 1 hour at 20°C. The plates were washed three times in wash buffer. Standards were
serially diluted, and samples were diluted at 1:4 dilution in PBS. The standards and samples were
added to the plates for a minimum of two hours at 20°C. The plates were washed, and the
appropriate detection antibody was diluted in assay buffer and 50 μL was applied to each well.
The plates were incubated at room temperature for 2 hours and then washed three times with
wash buffer. Following the wash, HRP streptavidin was diluted 1:40 in assay diluent and 50 μL
was added to each well for 20 minutes in the dark. The last wash of the plates was completed and
a 1:1 ratio of developing reagents A and B were mixed and 50 μL was added to each well. The
plates were incubated for up to 20 minutes in the dark until 25 μL of stop solution (2M sulfuric
acid) was added to each well. The plates were read at 450 nm using the program Synergy HTX
(BioTek, Winooksi, VT, USA).
Lactate Dehydrogenase (LDH) Assay
Cell death was evaluated through a LDH assay in cell culture supernatant using CyTox96
(Promega, Wisconsin, MI, USA), according to the manufacturer’s directions. In a flat
nonbinding 96-well plate, a standard curve was created with an LDH positive control (1:1000
dilution of LDH). Selected supernatant samples were diluted in assay buffer for at a total volume
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of 50 μL. 50 μL of substrate mix was added, and the plate was incubated in the dark at 22°C for
30 minutes. Following incubation, 50 μL of stop solution was added to each well. The plate was
then read at 450 nm using the program Synergy HTX (BioTek).
Statistical Calculations
Cell culture experiments were run in quadruplicates and repeated for reproducibility.
Graphs and corresponding error bars were created using GraphPad Prism 9.0 for Windows. Oneway ANOVAs with multiple comparisons were used to analyze data through GraphPad Prism
9.0. A p-value of *<0.05, **<0.01, ***<0.001, or ****<0.0001 from the multiple comparisons
was considered statistically significant.
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Results
24-hour treatment of varying adjuvants elicit a hypertrophic response in C2C12 myotubes
To determine the effects of adjuvants on myotube growth or atrophy, media containing
adjuvants (Table 1) was added to C2C12 myotubes and imaged 24 hours later. Images were
analyzed on ImageJ for myotube diameter size (Figure 3A, 3B). Myotube measurements showed
hypertrophic responses and significant increases in the diameter when compared to the control
group (DM Media). PAM3CSK4, MF59 (Addavax), Quil-A, and CFA induced significant
increases in myotube diameter 24 hours after adjuvant treatment (p<0.0001; Figure 3C). In
addition, AS03(Addas03) (p<0.001; Figure 3C) and LPS (p<0.01; Figure 3C) showed increases
in myotube diameter at 24 hours. Distribution of adjuvant conditions that had significant changes
in myotube diameter can be visualized (Figure 3D).
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Figure (3). A) Photograph of C2C12 myotubes 24 hours after the treatment of DM Media. B)
ImageJ measurements of individual myotube diameters based on previous image. C) 24h C2C12 average
myotube diameter for each adjuvant treatment. **p<0.01, ***p<0.001, ****p<0.0001 by one-way
ANOVA with multiple comparisons to the mean of the control (DM Media). D) 24h C2C12 individual
myotube diameter distribution of statistically significant adjuvants compared to DM media from Figure
C.

6-hour and 24-hour adjuvant treatment influences cytokine production in C212 myotubes
Previous literature has shown that following intramuscular injection of LPS or
PAM3CSK4, skeletal muscle upregulates several pro-inflammatory cytokines, including IL-6,
MCP-1, and IL-1534. To determine if skeletal muscle myocytes can express similar cytokines
following adjuvant stimulation, C2C12 myotubes were stimulated with varying adjuvants, using
LPS and PAM3CSK4 as positive controls. Supernatants of adjuvant stimulated C2C12 myotubes
were collected at 6 and 24 hours. IL-6 and MCP-1 production significantly increased at 24 hours
following LPS and PAM3CSK4 stimulation (p<0.0001; Figure 4A, 4B). IL-15 production at 24
hours was significantly downregulated by AS03 and non CpG 2138 (p<0.01; Figure 4C). IL-15
production was also significantly downregulated by CpG 1826 and CFA at 24 hours (p<0.05;
Figure 5C). These results suggest that skeletal muscle produce pro-inflammatory cytokines IL-6
and MCP-1 in response to positive controls of LPS and PAM3CSK4, but none of the typically
used adjuvants in vaccines. Additionally, adjuvants, including AS03, non CpG 2138, CpG 1826,
and CFA, may evoke a mechanism capable of lowering IL-15 production in skeletal muscle
myocytes.
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Figure (4). Cytokine production from C2C12 myotubes following stimulation with adjuvants, as assessed
at 24 hours. A) and B) **p<0.01, ***p<0.001, ****p<0.0001 and C) * p<0.05, **p<0.01 by one-way
ANOVA with multiple comparisons to the mean of the control (DM Media).
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Figure (5). Cytokine production from C2C12 myotubes following stimulation with adjuvants, as assessed
at 6 hours. A) IL-6 and B) MCP-1 (**p<0.01, ***p<0.001, ****p<0.0001) by one-way ANOVA with
multiple comparisons to the mean of the control (DM Media).
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IL-6 production was elevated in the C2C12 myotubes after stimulation with LPS,
PAM3CSK4, and Quil-A, although none of these values were seen to be statistically significant
by a one-way ANOVA. These results indicate that 6 hours may not be sufficient time to elicit a
significant IL-6 secretion by C2C12 cells. MCP-1 secretion significantly increased at 6 hours
following LPS stimulation (p<0.0001; Figure 5B). These results suggest that skeletal muscle
myocytes produce pro-inflammatory MCP-1 in response to the positive control of LPS, but none
of the typically used adjuvants in vaccines.
6-hour and 24-hour adjuvant treatment influences cytokine production in J774 macrophages
Previous literature has shown that the treatment of J774 macrophages with LPS elicits a
time and concentration dependent increase in IL-6 production35. To determine if macrophages
could express similar cytokines following adjuvant stimulation, J774 macrophages were
stimulated with varying adjuvants, using LPS and PAM3CSK4 as positive controls. Supernatants
of adjuvant stimulated J774 macrophages were collected in two separate experiments at 6 hours
and 24 hours.
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Figure (6). Cytokine production from J774 macrophages following stimulation with adjuvants, as
assessed at 6 hours. A) IL-6 and B) MCP-1 (****p<0.0001) by one-way ANOVA with multiple
comparisons to the mean of the control (DM Media).

IL-6 production by J774 macrophages was significantly increased at 6 hours by LPS
stimulation (p<0.0001; Figure 6A). The 6-hour treatment showed signs of elevated IL-6
production for PAM3CSK4 and CpG 1826 (Figure 6A). MCP-1 production by J774 macrophages
was significantly increased comparative to the control at 6 hours by LPS and PAM3CSK4
stimulation (p<0.0001; Figure 6B).
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Figure (7). Cytokine production from J774 macrophages following stimulation with adjuvants, as
assessed at 24 hours. A) IL-6 and B) MCP-1 (*p<0.05, ****p<0.0001) by one-way ANOVA with multiple
comparisons to the mean of the control (DM Media).

CpG 1826 stimulation only led to significant IL-6 secretion after the J774 macrophages
were stimulated for 24 hours (p<0.05; Figure 7A). LPS stimulation also led to significant IL-6
production after 24-hour stimulation (p<0.0001; Figure 7A) The 24-hour treatment showed signs
of elevated MCP-1 production for LPS and PAM3CSK4 (p<0.0001; Figure 7B). These results
show that only the positive controls of LPS and PAM3CSK4 elicit a pro-inflammatory MCP-1
response from J774 macrophages.
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Macrophages enhance adjuvant induced cytokine secretion in J774-C2C12 cocultures
Results of several studies led to the determination that a coculture of C2C12 myocytes
and J774 macrophages could give insight into if multiple cell types are needed to elicit a proinflammatory immune response by adjuvants. C2C12 myocytes were differentiated to day 7 and
on day 6, J774 macrophages were added to the C2C12 myotubes at a physiologically relevant
concentration. Adjuvant stimulation for 6 hours was conducted on day 7 and the supernatants
were collected.
Figure 8
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Figure (8). Cytokine production from C2C12 myocytes and J774 macrophages in coculture following
stimulation with adjuvants, as assessed at 6 hours. A) IL-6 and B) MCP-1 (**p<0.01, ***p<0.001,
****p<0.0001) by one-way ANOVA with multiple comparisons to the mean of the control (DM Media).

IL-6 production significantly increased at 6 hours following LPS, PAM3CSK4, and QuilA stimulation (p<0.0001, p <0.0001, p<0.001, respectively; Figure 8A). These results suggest
that adjuvant stimulation of cocultured myocytes and macrophages led to enhanced IL-6 and
MCP-1 production compared to the C2C12 myotubes in monoculture. MCP-1 production was
significantly increased at 6 hours following LPS and PAM3CSK4 stimulation (p<0.0001; Figure
8B).
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Cell death analysis of vaccine adjuvant treatment on C2C12 myotubes and J774 macrophages
To determine whether the lack of cytokine production from vaccine adjuvants was due to
their inability to stimulate a pro-inflammatory response, and not due to cytotoxicity, cell death
was assessed through measuring lactate dehydrogenase (LDH). This cytosolic enzyme is released
upon cell lysis and can serve as an indicator of cell damage. The amount of color formed by
LDH activity in the presence of a colorimetric substrate is proportional to the number of lysed
cells.

26

Figure 9
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Figure (9). Lactate dehydrogenase (LDH) cytotoxicity assay of varying cell types at different time points.
A) 6-hour C2C12 myotubes B) 24-hour C2C12 myotubes C) 6-hour J774 macrophages D) 24-hour J774
macrophages E) 6-hour coculture of C2C12 myotubes and J774 macrophages (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001) by one-way ANOVA with multiple comparisons to the mean of the control
(DM Media).

For the 6-hour C2C12 myotubes, high levels of LDH were found after adjuvant
stimulation with MF59, Quil-A, and AS03 compared to the control (p<0.0001; Figure 9A). For
the 24-hour C2C12 myotubes, LDH continued to increase in Quil-A and AS03 conditions
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compared to the DM media treatment (p<0.01, p <0.0001, respectively; Figure 9B).
Interestingly, LDH activity from MF59-treated myotubes returned to baseline levels at 24 hours
despite it being elevated at 6 hours. These results show that both Quil-A and AS03 were likely
promoting cell death of the myotubes. J774 macrophages were sensitive only to AS03 at both 6
(p<0.0001; Figure 9C) and 24 hours (p<0.001; Figure 9D). Finally, the 6-hour coculture showed
increased levels of LDH release with adjuvant stimulation by Quil-A, AS03, and CpG 1826
(p<0.001, p<0.001, p<0.05, respectively; Figure 9E).
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Discussion
Currently, adjuvant research is being conducted extensively due to its’ importance in the
development of effective vaccines. Adjuvants help by increasing IL-6, CCL2, and KC (CXCL1)
21

. Considering skeletal muscle has the potential to be an inflammatory tissue, we sought to

determine if current vaccine adjuvants would induce a response specifically in skeletal muscle
myocytes, and not by other resident cell types. Using an in vitro cell line of C2C12 mouse
skeletal myotubes we were able to investigate the hypothesis that muscle myocytes are an active
contributor to the pro-inflammatory response by adjuvants. We next began to simulate an in vivo
environment by adding macrophages in coculture with the C2C12 myotubes to determine
whether leukocytes augment the myotube response. Our data do not support the initial hypothesis
and suggest that there are additional influencers in skeletal muscle tissue that modulate adjuvant
induced pro-inflammatory cytokine production.
We first investigated growth effects of adjuvants on C2C12 myotubes. 24-hour exposure
caused an increase in cell diameter for the myotubes treated with PAM3CSK4, MF59, Quil-A,
CFA, AS03, and LPS (Figure 3A). This demonstrates that C2C12 muscle cells have the
capability to induce a hypertrophic response to adjuvants.
A popular explanation for myotube hypertrophy is the induction of MAPK and
mTOR/AMPK pathways. The mTOR/AMPK pathways are interlinked and involved in sensing
availability of nutrients and energy. AMPK is activated by the deficiency of energy which leads
to the inhibition of cell growth, while mTOR is switched on by energy availability which
promotes cell growth36. AMPK phosphorylation in the hypertrophying muscle is associated with
decreasing muscle hypertrophy and diminishing activity of the mTOR pathway37. Lactate, LPS,
IL-1, and TNF-α increases myotube diameter of C2C12 cells via the activation of the mitogen-
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activated protein kinases (MAPK)/extracellular signal-regulation kinases (ERK) pathway38. This
pathway also known as the Ras-Raf- MEK-ERK pathway is a chain of proteins within the cell
that communicates a signal from the surface of the cell to the DNA in the nucleus. Specifically,
the ERK pathway integrates external signals from mitogens into events to promote cell growth
and proliferation in different mammalian cell types. Mitogens are small bioactive proteins or
peptides that induce cells to enhance the rate of mitosis. They can also be considered nonspecific stimulants of immune cells. Extracellular lactate might have a positive effect on skeletal
muscle size, through lactate acting as a mitogen in the ERK pathway39. The selected adjuvants
that showed increases in cell diameter could also be acting as extracellular mitogens resulting in
the increase of size. The stimulation of TLRs, leading to their activation, is upstream of MAPK
activation. In agreement with our data, the TLR agonists, LPS and PAM3CSK4, induced a
hypertrophic response.
Many studies use C2C12 myotubes 3 to 4 days following differentiation40, whereas we
studied the myotubes following 7 days of differentiation. At 3 to 4 days, the myotubes may be
multinucleated, but do not terminally differentiate and form the bulk of actin/myosin complexes
until day 6 or day 741. In atrophy-based models, this means that researchers are often studying
growth inhibition of myotubes that are not fully differentiated42. Our studies contrast previous
literature reporting LPS causes atrophy in C2C12 myotubes40. Upon 24-hour stimulation, we
instead found evidence of hypertrophy. This result could be explained by the treatment of LPS
on terminally differentiated C2C12 myotubes.
The C2C12 myotubes stimulated by LPS and PAM3CSK4 increased IL-6 and MCP-1
production, whereas none of the other adjuvants appeared to show significant increases in these
cytokines at 6 and 24 hours (Figure 4A, 4B). In agreement with our data, previous in vivo studies
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have found that both LPS and PAM3CSK4 stimulate local secretion of IL-6 within skeletal
muscle following direct intramuscular injection34. The absence of a response by most adjuvants
led us to investigate other muscle-linked cytokines (myokines).
In previous literature, human skeletal muscle was found to constitutively produce low
levels of IL-15 without stimulation. Additionally, LPS was found to stimulate increased
production of IL-15 at 96 hours. Our LPS stimulation was performed for 24 hours and may not
have been sufficient time to measure an increase in IL-15 production in response to LPS or
PAM3CSK4 as compared to the control group43. This divergent result could be due to length of
stimulation (96h, 24h) or concentration of LPS (0.01 μg, 1 μg). Additionally, the other adjuvants
that caused decreases in IL-15 production may have evoked a mechanism that contributed to the
myocytes to decrease constitutive production of IL-15.
In vivo mouse skeletal muscle was producing cytokines and chemokines as early as 3
hours following injection of adjuvants, including MF59, Alum, and AS0144. Levels of those
proteins were shown to decrease rapidly within 24 hours after delivery. Additionally, certain
chemokines (Ccl2, Ccl4, Cc15, Cc112) were upregulated at time points ranging from 3 hours to
12 hours by CpG 1826 and MF5944. This information led to our decision to study an additional
6-hour time point. Cytokines were elevated in the LPS, PAM3CSK4, and Quil-A groups,
although not significantly at 6 hours (Figure 5A). These results lead to the conclusion that
additional time is needed to accumulate IL-6 in supernatant. Alternatively, C2C12 myotubes are
not responsible for the primary release of IL-6 after adjuvant stimulation. To the contrary, MCP1 production from 6 hours mirrored 24-hour production (Figure 4B, 5B). Both showed that
skeletal muscle produces abundant amounts of MCP-1 in response to LPS. Since no other
adjuvants induced this response, we conclude that skeletal muscle myocytes alone are not being
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induced to produce MCP-1 directly by the commonly used adjuvants. To address this, we began
investigating leukocytes as a possible enhancers of the skeletal muscle pro-inflammatory
response.
The immune response requires a myriad of cell types for proper function (Figure 2). After
exploring the effects of adjuvants on skeletal muscle myocytes in vitro by C2C12 myotubes, we
chose to investigate the effects of adjuvants on J774 murine macrophages. These cells were
chosen due to their bioavailability in muscle, rapid innate immune response, and their
accessibility. After 6-hour stimulation, we measured significant IL-6 production by treatment of
J774 macrophages with LPS (Figure 6A). At 24 hours, the J774 macrophages were producing
significant levels of IL-6 after stimulation by LPS and CpG 1826 (Figure 7A). CpG 1826 was
the first commonly used adjuvant (besides the positive controls of LPS and PAM3CSK4) to elicit
significant IL-6 production in either cell types used in our studies. CpG 1826 is used to activate
TLR9 and stimulate strong B cell activation. A previous study discovered that CpG dinucleotides
failed to increase IL-6 synthesis from C2C12 myocytes, suggesting that these cells do not
express functional TLR9. Further examination showed that they indeed lacked TLR9, and this
was also seen in mouse skeletal muscle. This supports our experiment since the results showed
that CpG 1826 stimulation of C2C12 myocytes did not elicit IL-6 production34. The J774
macrophages produced significant amounts of IL-6 in response to CpG 1826 showing that this
cell type contains TLR9 and that its’ activation helps to elicit an immune response.
The positive controls of LPS and PAM3CSK4 produced a potent MCP-1 response from
J774 macrophages (Figure 6B, 7B). This leads to the conclusion that the other adjuvants alone
lack the proper mechanisms induce muscle-derived cytokines. The prototypical inflammatory
pathways require the activation of NF-B or AP-1. Specifically, PAM3CSK4 induces MCP-1
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secretion through a TLR2-dependent, MyD88-dependent pathway45. It may be important to note
that macrophages can uptake and present soluble protein antigens and work similarly to dendritic
cells in this function. Macrophages activated through contact with pathogens or damage
associated molecular pattern(s) rapidly release cytokines and chemokines to recruit additional
immune cell types and further the actions surrounding an infection or vaccine. Our data suggest
that these cells alone are not responsible for adjuvant induced inflammation.
To determine if macrophages and muscle could enhance the cytokine production
following adjuvant stimulation, we created a coculture system. In coculture, Quil-A stimulation
led to significant increases in IL-6 production (Figure 8A). Quil-A is a saponin adjuvant reported
to induce a strong cytotoxic CD8+ lymphocytes response46. Previous studies showed that Quil-A
injected without antigen caused an increase in neutrophil recruitment and induced IL-6
production at the site of injection47. As IL-6 is responsible for stimulating the production of
neutrophils in borrow marrow48, Quil-A may elicit an increased IL-6 response to aid in the
production of neutrophils and their subsequent infiltration. MCP-1 production was only
increased at 6 hours in coculture by LPS and PAM3CSK4 leading to the possibility that the other
adjuvants are not capable of inducing MCP-1 production without an antigen (Figure 8B).
Additionally, we attempted to measure supernatant KC (CXCL1/IL-8) to determine if this
neutrophil chemoattractant was produced in mono- and cocultures. Unfortunately, the results
were inconclusive due to defects with the ELISA kit.
Cell death typically occurs by apoptosis, autophagy, or necrosis. The analysis of cell
death is imperative for adjuvant research because it encourages the testing of safer and more
effective adjuvants to be used in vaccines. LDH is a stable cytoplasmic enzyme found in cells
normally. When the plasma membrane of a cell is damaged, LDH is rapidly released into cell
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culture supernatant. THP-1 macrophages exposed to aluminum salts were predominantly similar
to untreated cells49 with regard to LDH release. Our experiments support this study that J774
macrophages exposed to aluminum salts had similar LDH release compared to the control.
In C2C12 myotubes, MF59, AS03, and Quil-A stimulation led to increases in LDH
release. In J774 macrophages, AS03 stimulation led to increased LDH release. In coculture,
adjuvant stimulation with AS03, Quil-A and CpG 1826 led to increased LDH release (Figure 9).
Previous studies have shown that the adjuvant AS03 stresses macrophages and leads to
activation of the endoplasmic reticulum (ER) stress sensor IRE1a50. Cells exposed to prolonged
or severe ER stress have been linked to the induction of apoptosis. Since AS03 induced high
levels of LDH in the observed treatments, one possible explanation is that AS03 caused both the
C2C12 myotubes and the J774 macrophages to induce ER stress. It can be assumed that the other
adjuvants may have also caused ER stress of the cells resulting in increased LDH release.
Monitoring the LDH release caused by adjuvants can be useful to determine which adjuvants
would be the best for human vaccine use. It could be important to note that Quil-A and AS03
have limited use in US vaccines for humans and the high levels of cell death induced could
potentially be the reason. Additionally, dying cells typically release pro-inflammatory molecules.
For example, IL-6 production of cocultured myotubes and macrophages was significant
stimulation with Quil-A. The Quil-A adjuvant also led to the highest amount of cell death for the
coculture. Additionally, IL-6 secretion of the 24-hour J774 cells was increased significantly by
CpG 1826 stimulation. This adjuvant also elicited a significant amount of cell damage in the
coculture although in these studies it is unclear which cell type contributed. The results of our
LDH assays contradict the visual evidence that the myotubes hypertrophied following adjuvant
treatment.
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The COVID-19 pandemic has brought new importance to vaccine and adjuvant research.
Unmodified mRNA changed to N1-methyl-pseudouridine-modifed mRNA is used to encode the
SARS-COVID-19 spike protein in vaccines. Pseudo uridine is used because normal uracil is
immunogenic and causes cells to not produce the protein as well as it could. To generate an
immune response, inflammation is pertinent. However, as it is relevant to mRNA vaccines, too
much inflammation can be provoked when the body recognizes the mRNA as viral mRNA. This
leads to cytoplasmic proteins to attach to it and mark it for destruction. Therefore, the mRNA is
modified to contain pseudo uridine to prevent that event from occurring. The vaccine mRNA is
delivered in a lipid nanoparticle (LNP) formulation. Different nucleotide substitution elicits
different immune responses, in addition to the LNPs increasing the efficacy of their delivery.
Adjuvants can be added readily to LNPs to increase the potency of the vaccine and guide the
direction of immune response. Protein vaccines encapsulating CpG ODNs with liposomes
showed an improved cellular immune response and different antibody response in comparison to
the protein alone17. Due to the complex nature of LNP formulations, true nanoparticles were not
able to be analyzed for this study. Instead, commercially available liposomes were substituted.
In conclusion, LPS and PAM3CSK4 elevated C2C12 myotube and J774 macrophage IL-6
and MCP-1 production at all time points. Other adjuvants, such as CpG 1826 and Quil-A,
elicited IL-6 production from J774 macrophages and in coculture, respectively. Many adjuvants,
including LPS, PAM3CSK4, MF59, AS03, Quil-A, and CFA increased the diameter of the C2C12
myotubes, which could indicate the possible connection between a growth pathway activation
and adjuvant stimulation.
The purpose of this study was to research adjuvants in vitro in the absence of antigens,
since most research is conducted in vivo with antigens. Additionally in the deltoid muscle, where
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vaccine injection typically occurs, many cell types, besides skeletal muscle cells and
macrophages are present. Some of these cell types include lymphocytes and neutrophils. Future
research should be directed towards in vitro efforts that contain more cell types in coculture to
create an environment more similar to that present in vivo. To this end, muscle organoids may
represent an attractive model system with which to study vaccine adjuvant responses51.
Additionally, adjuvants and antigens should be studied in combination to understand the full
potential of adjuvant stimulation. Adjuvant research is necessary to further discover the influence
these substances have in vaccines and which cell types they are responsible for stimulating.
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